FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 110 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... June 24, 2021 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 Choosing to act on cancer: Our Manifesto for Cancer Research and... April 20, 2023 Vaping Pods Produce High Nicotine Levels in Young Users October 5, 2018 Load more HOT NEWS Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up 4 Ways to Avoid Comparing Yourself to Others on Social Media... Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
